Pharming Group N.V. - ADR (PHAR)
Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript
Pharming Group N.V. (NASDAQ:PHAR ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Fabrice Chouraqui - CEO Stephen Toor - CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Ben Jackson – Jefferies Alistair Campbell - RBC Capital Markets Joe Pantginis - H.C.
European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug
On Wednesday, Pharming Group N.V. PHAR revealed topline results of data from its Phase 3 trial evaluating leniolisib in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).
Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript
Pharming Group N.V. (NASDAQ:PHAR ) Q3 2024 Earnings Conference Call October 24, 2024 7:30 AM ET Company Participants Sijmen de Vries - Chief Executive Officer & Executive Director Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participants Sushila Hernandez - Kempen Joe Pantginis - H.C.
Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript
Pharming Group NV (NASDAQ:PHAR ) Q2 2024 Earnings Conference Call August 1, 2024 7:30 AM ET Company Participants Sijmen de Vries - CEO & Executive Director Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Sushila Hernandez - Van Lanschot Kempen Jeff Jones - Oppenheimer Alistair Campbell - RBC Capital Markets Simon Scholes - First Berlin Sijmen de Vries Good morning or good afternoon, ladies and gentlemen; I'm here. Next slide, please.
